Liminatus Pharma is set to advance IBA101, a next-generation CD47 inhibitor designed to avoid the severe side effects that halted previous therapies, into human trials in the U.S. and Korea by early 2027. This innovative drug promises to redefine cancer immunotherapy by targeting tumors while sparing healthy cells, potentially offering new hope to patients.

Biomedical engineers at Georgia Tech have developed an experimental treatment that trains the immune system to recognize and eliminate hard-to-treat cancers. The approach showed success in lab tests without harming healthy tissues and prevented cancer from returning.

Context Therapeutics has reported its fiscal year 2024 results, highlighting significant strides in cancer immunotherapy. With strategic acquisitions and a strengthened financial position, the biotech firm is poised to advance its pipeline of T cell engaging bispecific antibodies targeting solid tumors.